Document is current

Article History

Received: 9 November 2020

Accepted: 13 January 2021

First Online: 1 February 2021

Ethics approval and consent to participate {24}

: This study has been IRB-approved at New York Presbyterian-Weill Cornell Medicine. This is protocol # 20-04021873, approved on October 2, 2020.Written informed consent of participants will be obtained by trained research assistants.Study participants will be assured that all responses will be kept confidential. All of the data collected during the interview process will be de-identified. Authorized study staff are the only individuals who have access to the participant’s personal information. This information is stored in a password-protected computer file as well as in a locked file cabinet in a locked office. All necessary precautions will be taken to ensure that there is no breach of confidentiality. As mentioned previously, confidentiality will only be broken upon an adverse event.

: The consent form for this trial is presented in Fig. InternalRef removed.The handout containing information about naltrexone [CitationRef removed] is presented in Fig. InternalRef removed.

: The authors declare that they have no competing interests.